Stavros G. Vizirgianakis - Oct 29, 2021 Form 4 Insider Report for Bioventus Inc. (BVS)

Role
Director
Signature
/s/ Anthony D'Adamio, Attorney-in-Fact
Stock symbol
BVS
Transactions as of
Oct 29, 2021
Transactions value $
$0
Form type
4
Date filed
11/2/2021, 04:17 PM
Previous filing
Jul 2, 2021
Next filing
Jun 22, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BVS Stock Option (Right to Buy) Award +26.2K 26.2K Oct 29, 2021 Class A Common Stock 26.2K $7.57 Direct F1, F2, F3
transaction BVS Stock Option (Right to Buy) Award +6.54K 6.54K Oct 29, 2021 Class A Common Stock 6.54K $3.33 Direct F1, F2, F3
transaction BVS Stock Option (Right to Buy) Award +19.6K 19.6K Oct 29, 2021 Class A Common Stock 19.6K $4.13 Direct F1, F2, F3
transaction BVS Stock Option (Right to Buy) Award +34.9K 34.9K Oct 29, 2021 Class A Common Stock 34.9K $12.27 Direct F1, F2, F3
transaction BVS Stock Option (Right to Buy) Award +347K 347K Oct 29, 2021 Class A Common Stock 347K $5.63 Direct F1, F2, F3
transaction BVS Stock Option (Right to Buy) Award +89K 89K Oct 29, 2021 Class A Common Stock 89K $7.78 Direct F1, F2, F3
transaction BVS Stock Option (Right to Buy) Award +262K 262K Oct 29, 2021 Class A Common Stock 262K $12.71 Direct F1, F2, F3
transaction BVS Restricted Stock Units Award $0 +2.9K $0.00 2.9K Oct 29, 2021 Class A Common Stock 2.9K Direct F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option is fully vested and exercisable.
F2 Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement);
F3 (continued from footnote 2) by (B) the Option Exchange Ratio (as defined in the Merger Agreement), rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent.
F4 Each restricted stock unit represents a contingent right to receive one share of Class A common stock
F5 The restricted stock units shall vest and become exercisable in three equal installments, with the first installment vesting and becoming exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant (such earlier date, the "Installment Vesting Date") and the second and third installments vesting and becoming exercisable on the first and second anniversaries of the Installment Vesting Date, respectively, in each case subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.